Buichi Fujitani

Novel, Highly Potent Aldose Reductase Inhibitors:  (<i>R</i>)-(−)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-<i>a</i>]pyrazine- 4-spiro-3‘-pyrrolidine-1,2‘,3,5‘-tetrone (AS-3201) and Its Congeners

Toshiyuki Negoro, Makoto Murata, S. UEDA et al. · Journal of Medicinal Chemistry · 1998 · 123 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

In Vivo Administration of a Nuclear Transcription Factor-κB Decoy Suppresses Experimental Crescentic Glomerulonephritis

Naruya Tomita, Ryuichi Morishita, Hui Y. Lan et al. · Journal of the American Society of Nephrology · 2000 · 114 citations

Medicine, Immunology, Pathology +17

Biochemical changes in unilateral brain injury in the rat: A possible role of free fatty acid accumulation

Junji Kuwashima, Buichi Fujitani, Keiji Nakamura et al. · Brain Research · 1976 · 63 citations

Life Sciences, Biochemistry, Neuroscience +16

Protective Effect of Zonisamide, an Antiepileptic Drug, Against Transient Focal Cerebral Ischemia with Middle Cerebral Artery Occlusion‐Reperfusion in Rats

Hisao Minato, Chie Kikuta, Buichi Fujitani et al. · Epilepsia · 1997 · 53 citations · Full text

Medicine, Neuroscience, Pharmacology +16

Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: A significant role of specific binding by serum albumin in the improved potency and stability

Masuo Kurono, Akihito Fujii, Makoto Murata et al. · Biochemical Pharmacology · 2005 · 41 citations

Life Sciences, Biochemistry, Medicinal Chemistry +10